| 生物活性 | PRMT5-IN-19 (Compound 41) is an orally active, non-nucleoside selective PRMT5 inhibitor with IC50 values of 23.9 nM (radioactive biochemical assay) and 47 nM (AlphaLISA assay) that occupies the SAM-binding pocket in PRMT5 and blocks methyltransferase activity, exhibits selectivity over PRMTs and PKMTs, and inhibits cell proliferation by inducing apoptosis, making it suitable for cancer-related research. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IC50 & Target |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 体外研究 (In Vitro) |
PRMT5-IN-19 (Compound 41, 5 days) has strong anti-proliferative effects against the A375 cell with an IC50 value of 1.36 μM. Cell Proliferation Assay
Western Blot Analysis
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 体内研究 (In Vivo) |
PRMT5-IN-19 (Compound 41, A375 xenograft model, 75 mg/kg/d, p.o., 19 days) has good PK properties and significant antitumor efficacy, without the obvious loss of body weight and visible toxicity.
|